Biotech | January 12, 2026
Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
